{"product_id":"bad-antibody-bcl2-associated-agonist-of-cell-death-bha17136229","title":"BAD Antibody \/ Bcl2-associated agonist of cell death","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\u003cp\u003eBAD Antibody \/ Bcl2-associated agonist of cell death is a anti-BAD Rabbit antibody Polyclonal (rabbit origin) supplied in Lyophilized format. Recommended for workflows such as Western blot (WB) with listed reactivity in Human, Mouse.\u003c\/p\u003e\u003ch2\u003eKey elements and design rationale\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eTarget:\u003c\/strong\u003e BAD\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAntibody details:\u003c\/strong\u003e Rabbit, Polyclonal (rabbit origin), isotype Rabbit IgG\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormat:\u003c\/strong\u003e Lyophilized\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eApplications (as listed):\u003c\/strong\u003e WB\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eBiological background\u003c\/h2\u003e\u003cdiv\u003eBAD antibody detects Bcl2-associated agonist of cell death, a pro-apoptotic member of the BCL2 protein family encoded by the BAD gene on chromosome 11q13.1. BAD is a cytoplasmic and mitochondrial-associated protein that regulates apoptosis by controlling mitochondrial outer membrane permeability. It is highly expressed in lymphoid tissues, liver, heart, and neurons, where it serves as a pivotal switch between cell survival and programmed cell death. BAD promotes apoptosis by binding to anti-apoptotic proteins BCL2 and BCL-XL, thereby freeing pro-apoptotic effectors such as BAX and BAK to induce cytochrome c release and caspase activation.\u003cbr\u003e\u003cbr\u003eUnder normal growth conditions, BAD remains phosphorylated and inactive, sequestered in the cytosol through association with 14-3-3 scaffold proteins. Upon cellular stress or growth factor deprivation, BAD becomes dephosphorylated by phosphatases such as PP2A, leading to its translocation to mitochondria and initiation of apoptosis. Functionally, BAD integrates signals from multiple pathways, including PI3K-AKT, MAPK, and cAMP-PKA, which regulate its phosphorylation state and apoptotic potential. Thus, BAD acts as a key convergence point for survival and death signals in diverse cell types.\u003cbr\u003e\u003cbr\u003eStructurally, BAD contains BH3 (Bcl2 homology 3) domains essential for heterodimerization with other BCL2 family proteins. This domain mediates selective binding that determines the balance between apoptosis inhibition and activation. Post-translational modifications such as phosphorylation at serine residues (Ser112, Ser136, and Ser155) and dephosphorylation events fine-tune BAD activity in response to extracellular cues. The protein localizes to mitochondria during apoptosis induction, where it promotes permeabilization of the mitochondrial outer membrane and triggers the intrinsic apoptotic cascade.\u003cbr\u003e\u003cbr\u003eDysregulation of BAD expression or phosphorylation contributes to cancer, neurodegenerative diseases, and ischemic injury. Overactivation of BAD leads to neuronal loss in neurodegenerative conditions, while reduced activity supports tumor cell survival and resistance to therapy. In cancer research, BAD phosphorylation status serves as a marker for apoptosis sensitivity and therapeutic response. BAD also plays a metabolic role in glucose homeostasis, influencing insulin secretion and mitochondrial respiration in pancreatic beta cells.\u003cbr\u003e\u003cbr\u003eBAD is a member of the BCL2 protein family, which governs mitochondrial apoptotic pathways by regulating membrane permeability and caspase activation. Pathway associations include the intrinsic apoptosis pathway and PI3K-AKT signaling, which modulate BAD phosphorylation and cellular survival. The protein's regulatory versatility makes it an important target in oncology, neurology, and metabolic research.\u003cbr\u003e\u003cbr\u003eImmunohistochemical staining using BAD antibody reveals cytoplasmic and mitochondrial localization in apoptotic cells. The BAD antibody from\u003c\/div\u003e\u003ch2\u003eResearch relevance and current trends\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003eConnecting protein-level changes to phenotype using orthogonal readouts (genetic perturbation, transcriptomics, imaging).\u003c\/li\u003e\n\u003cli\u003eConsidering isoforms and post-translational regulation when interpreting protein-level changes.\u003c\/li\u003e\n\u003cli\u003eComparing results across species and model systems with matched controls.\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eCommon research applications\u003c\/h2\u003e\u003cul\u003e\u003cli\u003e\n\u003cstrong\u003eWestern blotting:\u003c\/strong\u003e compare relative abundance and activation-state changes across conditions.\u003c\/li\u003e\u003c\/ul\u003e\u003cp\u003eInterpret changes in signal alongside appropriate controls and, when relevant, in parallel with total-protein or pathway readouts.\u003c\/p\u003e\u003ch2\u003eNotes for experimental interpretation\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003eSignal can reflect expression level, isoform composition, and post-translational state; interpret results in the context of your model system and stimuli.\u003c\/li\u003e\n\u003cli\u003eSpecies differences and sample matrices can influence epitope recognition; prioritize matched controls and orthogonal confirmation when feasible.\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003e\u003cstrong\u003eAntibody notes:\u003c\/strong\u003e Polyclonal antibodies recognize multiple epitopes, which can broaden the epitope footprint and may increase sensitivity in some contexts.\u003c\/p\u003e\u003c!-- Sources (internal): - UniProt search — UniProt — https:\/\/www.uniprot.org\/uniprotkb?query=BAD - NCBI Gene search — NCBI — https:\/\/www.ncbi.nlm.nih.gov\/gene\/?term=BAD - Ensembl search — Ensembl — https:\/\/www.ensembl.org\/Multi\/Search\/Results?q=BAD - Human Protein Atlas search — HPA — https:\/\/www.proteinatlas.org\/search\/BAD - PubMed (review) — NLM — https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=BAD+review --\u003e","brand":"NSJ Bioreagents","offers":[{"title":"Adding 0.2 ml of distilled water will yield a concentration of 500 ug\/ml \/ 100 ug","offer_id":53047322444141,"sku":"FY13327","price":449.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/get_image_78d01d7a-5a73-4bcf-9bb5-b231cd1f60e1.jpg?v=1782237110","url":"https:\/\/www.ebiohippo.com\/products\/bad-antibody-bcl2-associated-agonist-of-cell-death-bha17136229","provider":"BioHippo","version":"1.0","type":"link"}